Central Securities Holds Stake in Hess (HES); Suffolk Capital Management Increased Holding in Ligand Pharmaceuticals Incorpo (LGND)

April 22, 2018 - By Peter Erickson

Hess Corporation (NYSE:HES) Logo

Central Securities Corp increased its stake in Hess Corp (HES) by 19.15% based on its latest 2017Q4 regulatory filing with the SEC. Central Securities Corp bought 90,000 shares as the company’s stock rose 6.08% while stock markets declined. The institutional investor held 560,000 shares of the integrated oil company at the end of 2017Q4, valued at $26.58M, up from 470,000 at the end of the previous reported quarter. Central Securities Corp who had been investing in Hess Corp for a number of months, seems to be bullish on the $18.21 billion market cap company. The stock decreased 0.67% or $0.39 during the last trading session, reaching $57.81. About 4.38 million shares traded. Hess Corporation (NYSE:HES) has risen 8.91% since April 22, 2017 and is uptrending. It has underperformed by 2.64% the S&P500.

Suffolk Capital Management Llc increased its stake in Ligand Pharmaceuticals Incorpo (LGND) by 40.57% based on its latest 2017Q4 regulatory filing with the SEC. Suffolk Capital Management Llc bought 2,385 shares as the company’s stock rose 20.51% while stock markets declined. The institutional investor held 8,264 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.13M, up from 5,879 at the end of the previous reported quarter. Suffolk Capital Management Llc who had been investing in Ligand Pharmaceuticals Incorpo for a number of months, seems to be bullish on the $3.54B market cap company. The stock decreased 0.96% or $1.62 during the last trading session, reaching $166.98. About 153,051 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since April 22, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

Suffolk Capital Management Llc, which manages about $1.92B and $770.38 million US Long portfolio, decreased its stake in Fedex Corp (NYSE:FDX) by 7,033 shares to 71,696 shares, valued at $17.89M in 2017Q4, according to the filing. It also reduced its holding in Aci Worldwide Inc. (NASDAQ:ACIW) by 30,450 shares in the quarter, leaving it with 40,912 shares, and cut its stake in Penumbra Inc..

Investors sentiment decreased to 1.25 in Q4 2017. Its down 0.44, from 1.69 in 2017Q3. It worsened, as 21 investors sold LGND shares while 86 reduced holdings. 31 funds opened positions while 103 raised stakes. 22.68 million shares or 0.37% less from 22.76 million shares in 2017Q3 were reported. Tocqueville Asset Management LP reported 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). 55,061 were accumulated by Fisher Asset Lc. Great West Life Assurance Can holds 27,817 shares. Virginia Retirement Et Al holds 0.01% or 3,600 shares. Ls Invest Ltd Co accumulated 1,564 shares or 0.01% of the stock. Meridian Invest Counsel holds 0.24% or 3,145 shares. 3,284 were accumulated by Alpine Woods Invsts Limited Liability Company. Employees Retirement Of Texas holds 33,100 shares. Johnson Inv Counsel Inc stated it has 2,141 shares or 0.01% of all its holdings. Willingdon Wealth Management holds 15,075 shares. 489,830 are held by Conestoga Advsr Ltd. Prudential Financial Incorporated reported 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Martingale Asset Management Limited Partnership reported 16,502 shares. Vanguard Group has 0.01% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Janney Montgomery Scott Ltd Limited Liability Company has invested 0.04% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

Since December 20, 2017, it had 0 insider buys, and 12 sales for $16.28 million activity. KOZARICH JOHN W sold $401,063 worth of stock. 925 shares were sold by Sabba Stephen L, worth $126,956 on Wednesday, December 20. Another trade for 3,417 shares valued at $529,635 was sold by Aryeh Jason. Shares for $536,604 were sold by LAMATTINA JOHN L. 17,170 shares were sold by Davis Todd C, worth $2.62M on Monday, February 26. $832,824 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares were sold by FOEHR MATTHEW W.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 29 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Sell” rating by Deutsche Bank given on Monday, November 20. The rating was maintained by H.C. Wainwright on Wednesday, January 24 with “Buy”. The firm earned “Buy” rating on Monday, February 26 by Roth Capital. Craig Hallum maintained it with “Buy” rating and $170.0 target in Wednesday, November 15 report. As per Wednesday, April 13, the company rating was initiated by Stephens. Roth Capital maintained the shares of LGND in report on Monday, November 13 with “Buy” rating. On Monday, September 21 the stock rating was maintained by Roth Capital with “Buy”. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by TH Capital on Thursday, November 19. H.C. Wainwright maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Thursday, October 5 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Thursday, November 19.

Since February 8, 2018, it had 11 insider purchases, and 15 selling transactions for $8.38 million activity. Truelove Brian D. had sold 1,926 shares worth $85,572. 6,312 Hess Corporation (NYSE:HES) shares with value of $280,442 were sold by Hill Gregory P.. 3,808 shares were sold by Goodell Timothy B., worth $181,117. LAVIZZO-MOUREY RISA J bought 516 shares worth $25,016. SCHRADER WILLIAM G. had bought 516 shares worth $25,016. $135,592 worth of Hess Corporation (NYSE:HES) was sold by RIELLY JOHN P.

Investors sentiment increased to 0.94 in Q4 2017. Its up 0.06, from 0.88 in 2017Q3. It increased, as 45 investors sold HES shares while 161 reduced holdings. 63 funds opened positions while 131 raised stakes. 256.03 million shares or 0.61% more from 254.48 million shares in 2017Q3 were reported. 1St Source Retail Bank invested 0.02% in Hess Corporation (NYSE:HES). Millennium Mngmt Ltd Liability Co owns 0.05% invested in Hess Corporation (NYSE:HES) for 688,523 shares. Virtu Financial Lc reported 0.05% stake. Neville Rodie And Shaw holds 4,612 shares or 0.02% of its portfolio. Gateway Invest Advisers Lc holds 0.03% of its portfolio in Hess Corporation (NYSE:HES) for 86,632 shares. Balyasny Asset Management Limited Liability holds 71,742 shares or 0.01% of its portfolio. Quantbot Techs Lp has invested 0.17% in Hess Corporation (NYSE:HES). 200 were reported by Advisory Services Net Ltd Llc. Strs Ohio reported 1.27M shares. 317,846 were accumulated by Teachers Retirement System Of The State Of Kentucky. Arizona State Retirement, a Arizona-based fund reported 108,832 shares. Mitsubishi Ufj Tru & Banking reported 581,203 shares or 0.05% of all its holdings. 22,917 are held by Raymond James & Associates. Parkside National Bank & Trust And reported 169 shares stake. The Ontario – Canada-based Toronto Dominion Savings Bank has invested 0.02% in Hess Corporation (NYSE:HES).

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: